Last reviewed · How we verify

Drug: Semaglutide Administered SC

BrightGene Bio-Medical Technology Co., Ltd. · Phase 3 active Small molecule

Drug: Semaglutide Administered SC is a GLP-1 receptor agonist Small molecule drug developed by BrightGene Bio-Medical Technology Co., Ltd.. It is currently in Phase 3 development for Type 2 diabetes mellitus, Chronic weight management in obese or overweight patients, Cardiovascular risk reduction in patients with type 2 diabetes.

Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, suppress appetite, and promote weight loss.

Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, suppress appetite, and promote weight loss. Used for Type 2 diabetes mellitus, Chronic weight management in obese or overweight patients, Cardiovascular risk reduction in patients with type 2 diabetes.

At a glance

Generic nameDrug: Semaglutide Administered SC
SponsorBrightGene Bio-Medical Technology Co., Ltd.
Drug classGLP-1 receptor agonist
TargetGLP-1R
ModalitySmall molecule
Therapeutic areaDiabetes, Obesity, Cardiovascular
PhasePhase 3

Mechanism of action

Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion and reducing glucagon release. It also acts on the central nervous system to reduce appetite and increase satiety, leading to decreased caloric intake and weight reduction. These combined effects improve glycemic control and cardiovascular outcomes in patients with type 2 diabetes and obesity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Drug: Semaglutide Administered SC

What is Drug: Semaglutide Administered SC?

Drug: Semaglutide Administered SC is a GLP-1 receptor agonist drug developed by BrightGene Bio-Medical Technology Co., Ltd., indicated for Type 2 diabetes mellitus, Chronic weight management in obese or overweight patients, Cardiovascular risk reduction in patients with type 2 diabetes.

How does Drug: Semaglutide Administered SC work?

Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, suppress appetite, and promote weight loss.

What is Drug: Semaglutide Administered SC used for?

Drug: Semaglutide Administered SC is indicated for Type 2 diabetes mellitus, Chronic weight management in obese or overweight patients, Cardiovascular risk reduction in patients with type 2 diabetes.

Who makes Drug: Semaglutide Administered SC?

Drug: Semaglutide Administered SC is developed by BrightGene Bio-Medical Technology Co., Ltd. (see full BrightGene Bio-Medical Technology Co., Ltd. pipeline at /company/brightgene-bio-medical-technology-co-ltd).

What drug class is Drug: Semaglutide Administered SC in?

Drug: Semaglutide Administered SC belongs to the GLP-1 receptor agonist class. See all GLP-1 receptor agonist drugs at /class/glp-1-receptor-agonist.

What development phase is Drug: Semaglutide Administered SC in?

Drug: Semaglutide Administered SC is in Phase 3.

What are the side effects of Drug: Semaglutide Administered SC?

Common side effects of Drug: Semaglutide Administered SC include Nausea, Vomiting, Diarrhea, Constipation, Abdominal pain, Decreased appetite.

What does Drug: Semaglutide Administered SC target?

Drug: Semaglutide Administered SC targets GLP-1R and is a GLP-1 receptor agonist.

Related